Caledonia Rolls the Dice on Scientific Games With Massive Stake

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Caledonia Rolls the Dice on Scientific Games With Massive Stake

© Creativaimage / iStock via Getty Images

Scientific Games Corp. (NASDAQ: SGMS) was one of Monday’s big winners after the company announced that it had reached an agreement with a credentialed gaming industry investor to buy a significant stake in the company.

According to the deal, Caledonia will acquire a 34.9% stake in Scientific Games from MacAndrews & Forbes at a price of $28 per share. Also as part of this deal, Scientific Games is implementing a series of governance changes and enhancements, including refreshment of its board of directors.

Pursuant to the deal, the stockholders’ agreement with MacAndrews & Forbes will be terminated to reflect the new investor base.

As for the board of directors, it will be reconstituted to include all existing directors, other than the MacAndrews & Forbes representatives, as well as three new directors.

[nativounit]

The transaction between the investing parties and MacAndrews & Forbes is expected to be executed in multiple tranches, after which no investor is expected to beneficially own more than 9.9% of the outstanding shares of Scientific Games.

The first tranche sale is expected to be completed Monday, and the transaction is expected to be fully completed over the next several weeks. The changes to the Scientific Games Board become effective upon the first tranche sale.

As a result, the company more or less reiterated guidance for the full year. Scientific Games expects to see capital expenditures in the range of $210 million to $240 million, as well as positive free cash flow. Consensus estimates call for a net loss of $4.69 per share and $2.68 billion in revenue for the fiscal full year.

Scientific Games stock traded up about 46% Monday morning to $27.65, in a 52-week range of $3.76 to $31.63. The consensus price target is $19.70.

[recirclink id=737629][wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618